Mean change in pain (0–100 scale) Short term (3–12 weeks), where 0 = no pain · Patients with osteoarthritis of the knee or hip
Paracetamol showed no clear difference in mean change in pain (0–100 scale) Short term (3–12 weeks), where 0 =… compared with placebo (high certainty).
1 finding from 1 review
Physical function · Patients with osteoarthritis of the knee or hip
Paracetamol showed no clear difference in physical function (WOMAC function 0–100) compared with placebo (high certainty).
1 finding from 1 review
Quality of life Not measured · Patients with osteoarthritis of the knee or hip
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with osteoarthritis of the knee or hip
Paracetamol showed no clear difference in withdrawals due to adverse events 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events: number experiencing 24 weeks · Patients with osteoarthritis of the knee or hip
Paracetamol showed no clear difference in total adverse events: number experiencing 24 weeks compared with placebo (high certainty).
1 finding from 1 review
Liver toxicity: number experiencing abnormal liver function tests 24 weeks · Patients with osteoarthritis of the knee or hip
Paracetamol probably leads to higher liver toxicity: number experiencing abnormal liver function tests 24… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events: number experiencing 24 weeks · Patients with osteoarthritis of the knee or hip
Paracetamol showed no clear difference in serious adverse events: number experiencing 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review